Mink Therapeutics Inc INKT

$10.05 -0.55 (-5.19%)

Valuation

Market cap
55,061,000
Revenue TTM
$0
Net income TTM
$-12,490,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
15,600
Avg volume
15,612
Day's range
$9.61 – $10.59
Shares out
5,103,000
Stochastic %K
28%
Beta
0.49
Analysts
Moderate Buy
Price target
$42.50

Price

Company profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical...

Show more

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
212 994 8250
Website
https://minktherapeutics.com
Address
149 Fifth Avenue, Suite 500, New York, United States

Latest news

Stocktwits

enkemm Nov 3, 4:30 AM
$INKT The total treatment cost decreases dramatically when a patient avoids mechanical ventilation or only requires it for a very short duration, and the illness resolves within 7 to 14 days. Because intensive care costs are heavily tied to time spent on life support, shortening or eliminating the ventilation window removes the primary drivers of ARDS expense. An ARDS case that resolves without invasive mechanical ventilation generally mirrors the cost of a standard, uncomplicated pneumonia or acute respiratory infection hospitalization. Globally, this shifts the total cost down to a baseline range of $8,000 to $20,000, representing a 70% to 85% reduction in total resource expenditure. Thus...INKT charging 30,000 to 60,000 per patient treatment would save insurance companies hundreds of thousands of dollars in initial and follow up care. 120,000 cases a year in the US...3 million worldwide. Currently, no approved treatment. You tell me what T-797 is worth.... Pg2
0 replies
enkemm Nov 3, 4:29 AM
$INKT The average total treatment cost for a typical patient with Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation generally ranges between $30,000 and $130,000 for direct hospital expenses. However, this figure is highly dependent on the healthcare system, clinical complications, and geographic region. In the United States, due to distinct administrative structures, total hospital charges commonly scale much higher, ranging between $338,000 and $580,000 per episode of care. • By Severity (U.S. Trauma Cohorts): Severe ARDS patients often experience a shorter, more acute hospital course due to high early mortality, while those with milder ARDS who survive require prolonged management. • Mild ARDS: Average hospital charges of approximately $580,000 (~24 total hospital days). • Moderate ARDS: Average hospital charges of approximately $495,000 (~21 total hospital days). • Severe ARDS: Average hospital charges of approximately $338,000 (~14 total hospital days). Pg1
0 replies
weichsel1 Nov 2, 10:23 PM
$INKT Ignoring the cancer treatments, I think the stock market is undervaluing the potential pharma market in the ongoing ARDS market. This early study (2020 to 21) showed remarkable benefit. Even if there is only a 30 percent chance of success in the current phase 1/2/3 study, if successful it is a 2 to 5 Billion dollar drug (with or without competition). Expected value of 30 percent x 2Billion is 600m. Current market cap is 60 or 65m, fully diluted. So should be 10x higher now based on expected value), and if successful would be 20 to 40 times higher. https://www.nature.com/articles/s41467-024-44905-z
0 replies
focafoca99 Nov 2, 10:06 PM
$INKT details its upcoming Q3 2026 earnings release on Nov 11 and iNKT therapy progress update.
0 replies
enkemm Oct 30, 2:10 PM
$INKT OrientBeach...we should have a fairly good idea if AgenT-797 is the ARDS killer with the reporting of data from the Phase 2 trials in early 2027. IMO we are golden if the data shows a reduction to 10% mortality at 90 days. I do not believe that Rigel's drug can do this with ARDS, and to be a ball buster, it simply must. With good data, and given no current effective treatment for ARDS and the outrageous daily cost of ICU care for ventilated ARDS patients....I anticipate INKT stock could move to the $35 to $50 per share range. Ah.....pipe dreams are very pleasant....are they not?
1 replies
enkemm Oct 29, 6:23 AM
$INKT OceanBeach...here is what AI says when comparing INKT's Agent 797 with RIGL's drug The Crucial Differences in Their Likelihood of Success 1. Definitive Failure vs. Active Development • Fostamatinib: While it had theoretical backing early in the pandemic, its high-level failure in a 400-patient Phase 3 trial published in JAMA Network Open has minimized the likelihood of it ever becoming an approved or recommended ARDS treatment. • agenT-797: Developed by MiNK Therapeutics (NASDAQ: INKT), this therapy is on an upward trajectory. Following successful exploratory trials published in Nature Communications, MiNK launched a randomized Phase 2 trial (Trial NCT07615010) evaluating the drug across severe pneumonia-induced ARDS. (Page 1)
1 replies
enkemm Oct 29, 6:15 AM
$INKT Summary of Likelihood If you are evaluating these from a perspective of clinical hope or future availability, agenT-797 is a highly anticipated pipeline candidate with strong foundational data, whereas fostamatinib has been clinically ruled out for standard ARDS care. (Page 3)
0 replies
enkemm Oct 29, 6:14 AM
$INKT 2. The "Smart Cell" Advantage Fostamatinib is a blunt chemical hammer designed to shut down an inflammatory pathway. In contrast, agenT-797 utilizes unmodified invariant Natural Killer T (iNKT) cells. Data presented at the American Society of Gene and Cell Therapy (ASGCT) confirmed that these cells naturally adapt to their environment—driving inflammation to kill cancer tumors, but shifting to an anti-inflammatory "healing" program when inside a damaged, failing lung. 3. Pathogen Clearance & Secondary Infection Prevention A major risk for ARDS patients on ventilators is acquiring secondary bacterial pneumonia. Fostamatinib does not help fight off secondary infections. Conversely, early trial data for agenT-797 showed an 80% reduction in secondary bacterial pneumonia at the highest dose. Because iNKT cells naturally preserve the patient’s ability to clear pathogens, they keep the body equipped to fight secondary hospital infections while calming the primary ARDS damage. (Page 2)
0 replies